Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (Diluted Average) (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $62.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 15.28% to $62.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $62.0 million, a 15.28% increase, with the full-year FY2025 number at $62.0 million, up 15.28% from a year prior.
  • Shares Outstanding (Diluted Average) was $62.0 million for Q4 2025 at Janux Therapeutics, roughly flat from $61.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $62.0 million in Q4 2025 to a low of $5.6 million in Q2 2021.
  • A 5-year average of $45.4 million and a median of $43.1 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Biggest YoY gain for Shares Outstanding (Diluted Average) was 639.38% in 2022; the steepest drop was 0.72% in 2022.
  • Janux Therapeutics' Shares Outstanding (Diluted Average) stood at $23.5 million in 2021, then surged by 76.24% to $41.5 million in 2022, then increased by 6.14% to $44.0 million in 2023, then increased by 22.12% to $53.8 million in 2024, then rose by 15.28% to $62.0 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Shares Outstanding (Diluted Average) are $62.0 million (Q4 2025), $61.9 million (Q3 2025), and $61.8 million (Q2 2025).